[The antitumor properties of 3,5-diglycoside-cyanidine].
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage* / Q000633:toxicity; D006027:Glycosides / Q000008:administration & dosage / Q000633:toxicity; D007274:Injections, Intraperitoneal; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy
D000970:Antineoplastic Agents; D005419:Flavonoids; D006027:Glycosides
O protivoopukholevykh svoĭstvakh 3,5-diglikozid-tsianidina.